Medications for Leukemia Acute Myeloid Leukemia Aml

9 results

  • daurismo

    (glasdegib)
    Pfizer Laboratories Div Pfizer Inc
    DAURISMO, in combination with low-dose cytarabine, is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults aged ≥75 or with comorbidities that prevent the use of intensive induction chemotherapy.

  • idhifa

    (enasidenib mesylate)
    Celgene Corporation
    IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have an IDH2 mutation, confirmed by an FDA-approved test.

  • mylotarg

    (gemtuzumab ozogamicin)
    Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
    MYLOTARG is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients aged 1 month and older, as well as for relapsed or refractory CD33-positive AML in adults and pediatric patients aged 2 years and older.

  • onureg

    (azacitidine)
    Celgene Corporation
    ONUREG is indicated for the continued treatment of adults with acute myeloid leukemia who have achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) after intensive induction chemotherapy and are unable to complete intensive curative therapy.

  • rezlidhia

    (olutasidenib)
    Rigel Pharmaceuticals, Inc.
    REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as confirmed by an FDA-approved test.

  • vanflyta

    (QUIZARTINIB)
    Daiichi Sankyo Inc.
    VANFLYTA is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 ITD-positive. It is used in combination with chemotherapy for induction and consolidation, and as maintenance monotherapy post-consolidation. Not for use after allogeneic stem cell transplantation.

  • venclexta

    (Venetoclax)
    AbbVie Inc.
    VENCLEXTA is indicated for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is also indicated in combination with azacitidine, decitabine, or low-dose cytarabine for treating newly diagnosed acute myeloid leukemia (AML) in patients 75 and older or with comorbidities.

  • vyxeos

    ((daunorubicin and cytarabine) liposome)
    Jazz Pharmaceuticals, Inc.
    VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients aged 1 year and older.

  • xospata

    (gilteritinib)
    Astellas Pharma US, Inc.
    XOSPATA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring a FLT3 mutation, confirmed by an FDA-approved test.